Functional analysis of HOXD9 in human gliomas and glioma cancer stem cells

Table 1 Association of HOXD9 expression and MIB-1 index in glioma tissues

*Case no*	*Histology*	*Age (years)*	*Sex*	*MIB-1(%)* ^a	*Immunohistochemistry* ^b
WHO grade IV
GB1	Glioblastoma	60	M	40.7	+++
GB2	Glioblastoma	79	F	44.8	+++
GB3	Glioblastoma	72	M	9.1	+
GB4	Glioblastoma	55	F	14.0	+
GB5	Glioblastoma	34	M	8.0	+
GB6	Glioblastoma	28	M	53.0	+++
GB7	Glioblastoma	33	M	8.1	++
GB8	Glioblastoma	55	F	37.2	+++
GB9	Glioblastoma	69	M	30.1	++
GB10	Glioblastoma	38	M	36.4	+
GB11	Glioblastoma	61	F	23.8	+
GB12	Glioblastoma	53	F	11.2	+
GB13	Glioblastoma	60	F	20.4	+
WHO grade III
AA1	Anaplastic astrocytoma	50	F	0.8	+++
AA2	Anaplastic astrocytoma	77	F	2.6	+
AA3	Anaplastic astrocytoma	36	M	1.2	++
AA4	Anaplastic astrocytoma	76	F	34.2	+
AA5	Anaplastic astrocytoma	39	M	2.2	++
AA6	Anaplastic astrocytoma	27	M	5.2	+
AA7	Anaplastic astrocytoma	52	F	19.6	+++
AA8	Anaplastic astrocytoma	45	F	4.0	-
AA9	Anaplastic astrocytoma	27	F	7.8	-
AA10	Anaplastic astrocytoma	39	F	3.2	+++
AA11	Anaplastic astrocytoma	9	F	1.6	+
WHO grade II
DA1	Diffuse astrocytoma	37	M	4.5	+
DA2	Diffuse astrocytoma	36	M	3.0	++
DA3	Diffuse astrocytoma	3	M	2.9	++
DA4	Diffuse astrocytoma	50	M	1.7	-
DA5	Diffuse astrocytoma	10	M	2.4	++

^a The proliferating cell index was analyzed in >1000 tumor cells in more than three areas expressing the highest number of MIB-1-positive nuclei. ^b The patterns of HOXD9 staining are described as (-) negative or faint staining; (+) positive in less than 30% of tumor cells; (++) positive in less than 70% of tumor cells; (+++) positive in more than 70% of tumor cells. M, male; F, female.

ISSN: 1476-4598